Literature DB >> 18625429

Hepatitis C infection and nonalcoholic fatty liver disease.

Onpan Cheung1, Arun J Sanyal.   

Abstract

In hepatitis C virus (HCV) infection, significant hepatic steatosis or superimposed nonalcoholic steatohepatitis is associated with disease severity and poor response to antiviral therapy. Nonalcoholic fatty liver disease (NAFLD) and HCV are common causes of chronic liver disease in Western countries and are strongly linked to concurrent obesity, insulin resistance, and the metabolic syndrome. With the escalating prevalence of obesity in North America, insulin resistance and the metabolic syndrome are major public health problems that have a significant impact on morbidity and mortality associated with NAFLD and HCV. This article focuses on the current understanding of the interplay between host and viral factors that are involved in the interaction between NAFLD and HCV.

Entities:  

Mesh:

Year:  2008        PMID: 18625429     DOI: 10.1016/j.cld.2008.03.005

Source DB:  PubMed          Journal:  Clin Liver Dis        ISSN: 1089-3261            Impact factor:   6.126


  8 in total

1.  Hepatic lipogranulomas in patients with chronic liver disease: association with hepatitis C and fatty liver disease.

Authors:  Hongfa Zhu; Henry C Bodenheimer; David J Clain; Albert D Min; Neil D Theise
Journal:  World J Gastroenterol       Date:  2010-10-28       Impact factor: 5.742

2.  Prevalence and predictors of low muscle mass in HIV/viral hepatitis coinfection.

Authors:  Charitha Gowda; Todd T Brown; Charlene Compher; Kimberly A Forde; Jay Kostman; Pamela A Shaw; Phyllis C Tien; Vincent Lo Re
Journal:  AIDS       Date:  2016-10-23       Impact factor: 4.177

Review 3.  Fat: a matter of disturbance for the immune system.

Authors:  Alessandro Federico; Elena D'Aiuto; Francesco Borriello; Giusi Barra; Antonietta Gerarda Gravina; Marco Romano; Raffaele De Palma
Journal:  World J Gastroenterol       Date:  2010-10-14       Impact factor: 5.742

Review 4.  Kupffer cells in non-alcoholic fatty liver disease: the emerging view.

Authors:  György Baffy
Journal:  J Hepatol       Date:  2009-03-31       Impact factor: 25.083

Review 5.  Radiologic evaluation of nonalcoholic fatty liver disease.

Authors:  Seung Soo Lee; Seong Ho Park
Journal:  World J Gastroenterol       Date:  2014-06-21       Impact factor: 5.742

Review 6.  Infections at the nexus of metabolic-associated fatty liver disease.

Authors:  Robim M Rodrigues; Tamara Vanhaecke; Joost Boeckmans; Matthias Rombaut; Thomas Demuyser; Baptist Declerck; Denis Piérard; Vera Rogiers; Joery De Kock; Luc Waumans; Koen Magerman; Reinoud Cartuyvels; Jean-Luc Rummens
Journal:  Arch Toxicol       Date:  2021-05-24       Impact factor: 5.153

7.  A prospective comparative assessment of the accuracy of the FibroScan in evaluating liver steatosis.

Authors:  Baek Gyu Jun; Won Young Park; Eui Ju Park; Jae Young Jang; Soung Won Jeong; Sae Hwan Lee; Sang Gyune Kim; Sang-Woo Cha; Young Seok Kim; Young Deok Cho; Hong Soo Kim; Boo Sung Kim; So Young Jin; Suyeon Park
Journal:  PLoS One       Date:  2017-08-15       Impact factor: 3.240

8.  Comparing the controlled attenuation parameter using FibroScan and attenuation imaging with ultrasound as a novel measurement for liver steatosis.

Authors:  Po-Ke Hsu; Li-Sha Wu; Wei-Wen Su; Pei-Yuan Su; Yang-Yuan Chen; Yu-Chun Hsu; Hsu-Heng Yen; Chia-Lin Wu
Journal:  PLoS One       Date:  2021-10-15       Impact factor: 3.752

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.